Racura Oncology (ASX:RAC): First Patient Dosed in HARNESS-1 Starts the Clinical Clock

Aditi Sarkar

31 July 2026 03:19 PM AEST

Racura Oncology (ASX:RAC): First Patient Dosed in HARNESS-1 Starts the Clinical Clock

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Racura Oncology has dosed the first patient in its Phase 1 HARNESS-1 clinical trial.
The company expanded the study to additional Australian cancer treatment centres.
RC220 remains the company's lead oncology asset across multiple development programs.
Investors are monitoring future clinical data, trial enrolment and funding progress.

Racura Oncology (ASX:RAU) has entered a new stage of clinical development after dosing the first patient in its Phase 1 HARNESS-1 study during June 2026. Following its rebrand from Race Oncology, the company is advancing its lead therapy, RC220, while expanding clinical trial sites and progressing multiple development programs.

A rebrand and a new phase

Formerly known as Race Oncology, Racura Oncology officially adopted its new corporate identity in December 2025 while retaining the ASX ticker RAC. The rebranding coincided with the company's transition from preclinical research into active clinical development, marking an important milestone for its lead drug candidate, RC220.

RC220 is a proprietary reformulation of bisantrene, designed for peripheral intravenous administration and developed to target the c-MYC cancer-growth pathway in selected oncology indications.

The HARNESS-1 catalyst

On 25 June 2026, Racura Oncology announced that the first patient had been dosed in its Phase 1 HARNESS-1 clinical trial evaluating RC220 in patients with EGFR-mutant non-small-cell lung cancer at Monash Health in Victoria. This milestone marked the commencement of patient treatment rather than the release of clinical efficacy or safety data.

Shortly afterwards, the company received ethics approval to expand the HARNESS-1 study to two additional Australian hospitals—Chris O'Brien Lifehouse in Sydney and Austin Health in Melbourne—broadening recruitment capacity.

RC220 is also being evaluated through additional development programs, including a planned Phase 3 study in acute myeloid leukaemia and a Phase 1 cardioprotection trial involving patients receiving doxorubicin chemotherapy.

Trial design and finances

HARNESS-1 is structured as a Phase 1 dose-escalation study designed to enrol approximately 12 to 40 participants before expanding into a larger Phase 1b cohort of around 40 patients. The trial is evaluating RC220 in combination with AstraZeneca's osimertinib, with primary objectives including safety, tolerability and pharmacokinetics, together with exploratory measures of clinical activity.

Racura Oncology reported cash of A$19.38 million at 31 March 2026. During mid-2026, the company also completed additional funding activities, with management indicating that available capital is expected to support ongoing clinical development. The June-quarter cash balance had not been independently confirmed at the time of writing.

Industry context

Racura Oncology operates within the clinical-stage biotechnology sector, where company valuations are primarily driven by clinical milestones rather than commercial revenue. Phase 1 studies are designed to establish safety and determine appropriate dosing before larger efficacy studies can begin. Regulatory progress, clinical data and potential strategic partnerships typically represent important value drivers for companies developing investigational oncology therapies.

The EGFR-mutant non-small-cell lung cancer market remains an active area of oncology research, with significant interest in therapies capable of addressing treatment resistance.

The bull case

Supporters highlight the company's rapid clinical execution following the first patient dosing, expansion to additional treatment centres and progress across multiple RC220 development programs. Racura Oncology has also strengthened its financial position through recent funding initiatives while advancing a differentiated therapeutic approach targeting c-MYC biology alongside potential cardioprotective applications. The company's diversified clinical strategy provides several opportunities for future data generation.

The bear case and risks

RC220 remains in the early stages of clinical development, and no efficacy or safety data from HARNESS-1 have yet been reported. Clinical trials carry significant development risk, and larger studies will be required before any conclusions can be drawn regarding therapeutic benefit. Progressing multiple clinical programs may also require additional funding over time, while success in the competitive oncology landscape remains dependent on future clinical outcomes.

What to watch next

Investors are expected to monitor dose-escalation progress, patient recruitment across the expanded clinical sites and the first safety and pharmacokinetic results from HARNESS-1. Additional areas of interest include updates on the planned Phase 3 acute myeloid leukaemia program, progress in the cardioprotection study, future quarterly cash flow reports and any strategic partnership or licensing developments involving RC220.

Racura Oncology has reached an important milestone by commencing clinical evaluation of RC220. The company's next stage of development will depend on generating clinical evidence that supports further advancement while maintaining sufficient funding to execute its broader oncology strategy.

FAQs

Q: What is Racura Oncology's lead drug candidate?

A:RC220, a reformulated version of bisantrene, is the company's lead oncology therapy currently undergoing clinical evaluation.

Q: What is the HARNESS-1 trial?

A:HARNESS-1 is a Phase 1 clinical trial evaluating RC220 in combination with osimertinib for patients with EGFR-mutant non-small-cell lung cancer.

Q: Has Racura Oncology reported clinical trial results?

A:No. The company has announced the first patient dosing and trial expansion, but clinical safety and efficacy data have not yet been released.

Q: What other clinical programs is the company developing?

A:Racura Oncology is also progressing a planned Phase 3 acute myeloid leukaemia study and a Phase 1 cardioprotection trial involving RC220.

Q: What are the next milestones for Racura Oncology?

A:Investors will be watching patient recruitment, early clinical data from HARNESS-1, progress across the broader RC220 development program, future funding updates and potential strategic partnerships.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.